THE PLACE OF COMBINATION ANTIHYPERTENSIVE DRUGS IN NEPHROPROTECTIVE THERAPY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper analyzes the pathogenetic aspects of and main treatment options for arterial hypertension (AH) associated with renal lesion. It provides a rationale for the important role of combination drugs, a combination of lisinopril and amlodipine in particular, in nephroprotective therapy aimed not only at normalizing AH, but also reducing the rate of progression of nephropathy.

Full Text

Restricted Access

About the authors

I. Kolina

I.M. Sechenov First Moscow State Medical University

Email: ikolina@yandex.ru
Candidate of Medical Sciences

References

  1. Дзизинский А. А., Протасов К. В., Федоришина О. В.и др. Фиксированная комбинация ингибитора ангиотензинпревращающего фермента и антагониста кальция в лечении больных артериальной гипертензией // Системные гипертензии. - 2011; 1: 52-57.
  2. Кутырина И. М., Мартынов С. А., Швецов М. Ю. и др. Артериальная гипертония при хроническом гломерулонефрите: частота выявления и эффективность лечения // Тер. арх. - 2004; 9: 10-15. ВРАЧ 4'2012
  3. Кутырина И. М., Руденко Т. Е., Швецов М. Ю. и др. Факторы риска сердечнососудистых осложнений у больных на додиализной стадии хронической почечной недостаточности // Тер. арх. - 2006; 5; 45-50.
  4. Фомин В. В., Моисеев С. В., Швецов М. Ю. и др. Артериальная гипертония при ишемической болезни почек: клинические особенности и течение // Тер. арх. -2005; 6: 27-32.
  5. Чазова И. Е., Ратова Л. Г., Недогода С.В.и др. Фиксированная комбинация ингибитора ангиотензинпревращающего фермента и антагониста кальция в лечении больных артериальной гипертензией // Системные гипертензии. - 2011; 3: 21-25.
  6. Agarwal R., Light R. P GFR, proteinuria and circadian blood pressure // Nephrol. Dial. Transplant. - 2009; 24: 2400-2406.
  7. de Leeuw P., Thijs L., Birkenhager W. et al. For the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Prognostic Significance of Renal Function in Elderly Patients with Isolated Systolic Hypertension: Results from the Syst-Eur Trial // J. Am. Soc. Nephrol. - 2002; 13: 2213-2222.
  8. Dworkin L., Weir M. Hypertension in renal parenchimal disease: role in progression. In: Mechanisms and clinical management of chronic renal failure. Ed. El Nahas A. M., Harris K. P. G., Anderson S. 2 nd edition. Oxford University Press, 2000. -173-210.
  9. Epstein M. Calcium antagonists in the management of hypertension. In: Epstein M., editor. Calcium antagonists in clinical medicine. 3 rd edition. Philadelphia: Hanley and Belfus; 2002. - 293-313.
  10. Fujita T., Ando K. Salt, Blood Pressure, and kidney. In: Kidney and Blood Pressure Regulation. Ed. Suzuki H., Saruta T. Contributions to Nephrology. Karger, Basel, 2004. - 16-31, 20.
  11. Hsu C. et al. Elevated blood pressure and risk for end-stage renal disease in subjects without baseline kidney disease // Arch. Intern. Med. - 2005; 165: 923-928.
  12. Jamerson K., Weber M., Bakris G. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients // N. Engl. J. Med.- 2008; 359: 2417-2428.
  13. Julius S., Kjeldsen S., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial // Lancet. - 2004; 363 (9426): 2022-2023.
  14. Kearney P. et al. Global burden of hypertension: analysis of worldwide data // Lancet. - 2005; 365: 217-223.
  15. Kearney P., Whelton M., Reynolds K. et al. Worldwide prevalence of hypertension: a systematic review // J. Hypertens. - 2004; 22: 11-19.
  16. Khosla, N., Kalaitzidis R., Bakris G. The kidney, hypertension and remaining challenges // Med. Clin. N. Am. - 2009; 93: 697-715.
  17. Kidney Disease: Improving Global Outcomes [online], www.kdigo.org
  18. Klag M.et al.Blood pressureand end-stage renaldiseaseinmen // N. Engl. J. Med. -1996; 334: 13-18.
  19. Kunz R., Friedrich C., Wolbers M. et al. Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease // Ann. Intern. Med. - 2008; 148: 30-48.
  20. Lea J., Green T., Hebert L. et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension // . Arch. Intern. Med.- 2005; 165 (8): 947-953.
  21. Van der Velde M., Matsushita K., Coresh J. et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts // Kidney International. - 2011; 79: 1341-1352.
  22. Moser M. h e ASCOT trial // J. Clin. Hypertens. (Greenwich). - 2005; 7 (12): 748-750.
  23. Peterson J., Adler S., Burkart J. et al. Blood pressure control, proteinuria and the progression of renal disease: the Modification of Diet in Renal Disease study // Ann. Intern. Med. - 1995; 123: 754-762.
  24. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) // JAMA. - 2002; 288: 2981-2997.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies